PRESS RELEASE published on 11/14/2024 at 15:31, 6 days 22 hours ago Further expansion of cost reduction programme Novacyt announces further expansion of cost reduction programme with proposed site consolidations expected to deliver c. £2.0m EBITDA improvement, including closure of Eastleigh site and transfer of Canada manufacturing operations to Manchester Cost Reduction EBITDA Improvement Manufacturing Operations Novacyt Site Consolidations
BRIEF published on 11/14/2024 at 15:31, 6 days 22 hours ago Novacyt launches new veterinary tests Gastrointestinal Diseases Novacyt Molecular Diagnosis Veterinary Tests Pathogens
BRIEF published on 11/01/2024 at 14:00, 19 days 23 hours ago Novacyt: Update on liquidity contract and voting rights Common Shares Voting Rights Liquidity Contract INVEST SECURITIES Novacyt
BRIEF published on 11/01/2024 at 13:57, 19 days 23 hours ago Novacyt Updates on Liquidity Agreement and Voting Rights Liquidity Agreement INVEST SECURITIES Total Voting Rights French Law Novacyt Shares
PRESS RELEASE published on 11/01/2024 at 13:52, 19 days 23 hours ago Liquidity Agreement and Total Voting Rights Novacyt provides liquidity agreement update and total voting rights information, with Invest Securities purchasing and selling ordinary shares. Company divided into clinical, instrumentation, and research use segments Ordinary Shares Liquidity Agreement Total Voting Rights Novacyt Clinical Diagnostics
BRIEF published on 10/31/2024 at 10:28, 21 days 3 hours ago Dr. Ian Gilham Joins Novacyt as Non-Executive Director Life Sciences Board Appointment Non-Executive Director Novacyt Dr. Ian Gilham
BRIEF published on 10/31/2024 at 10:25, 21 days 3 hours ago Appointment of Dr Ian Gilham to the Board of Directors of Novacyt Board Of Directors Life Sciences Appointment Novacyt Ian Gilham
PRESS RELEASE published on 10/31/2024 at 10:23, 21 days 3 hours ago Directorate Change Novacyt appoints Dr Ian Gilham as Non-Executive Director, bringing expertise in life sciences companies to strengthen the Board Life Sciences Non-Executive Director Novacyt Dr Ian Gilham AIM-listed
BRIEF published on 10/17/2024 at 11:47, 1 month 4 days ago IVDR Certification for Yourgene® Cystic Fibrosis Test by Novacyt Screening Novacyt IVDR Cystic Fibrosis Yourgene
BRIEF published on 10/10/2024 at 12:28, 1 month 11 days ago Novacyt closes its IT-IS International subsidiary EBITDA Closing Novacyt IT-IS International PCR Market
Published on 11/21/2024 at 13:00, 36 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 36 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 36 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 36 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 36 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 1 hour 1 minute ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 21 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 38 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 16 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 51 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 51 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
